ginisortamab (UCB6114)

News alerts, weekly reports and conference planners

Company:

UCB

Drug class:

Gremlin-1 modulator

‹

›

almost2years

ONC001: A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=95, Completed, UCB Biopharma SRL | Active, not recruiting --> Completed

almost 2 years ago

Trial completion • Metastases

5-fluorouracil • oxaliplatin • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • ginisortamab (UCB6114)

2years

ONC001: A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=95, Active, not recruiting, UCB Biopharma SRL | Recruiting --> Active, not recruiting | N=250 --> 95 | Trial completion date: Feb 2024 --> May 2024 | Trial primary completion date: Feb 2024 --> May 2024

2 years ago

Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases

5-fluorouracil • oxaliplatin • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • ginisortamab (UCB6114)

over3years

Binding characteristics and preclinical activity of UCB6114; the first fully human anti-gremlin-1 monoclonal antibody in development for the treatment of cancer (EACR 2022)

Conclusion UCB6114; the first human, highly selective, IgG4P mAb optimised for activity against human gremlin-1 protein, demonstrated restoration of gremlin-1-ablated BMP signalling. UCB6114 is in a Phase I/II clinical trial in patients with advanced solid tumours (NCT04393298).

over 3 years ago

Preclinical

ID2 (Inhibitor Of DNA Binding 2) • TGFB1 (Transforming Growth Factor Beta 1) • ID3 (Inhibitor Of DNA Binding 3, HLH Protein)

ginisortamab (UCB6114)